The Influence of Juvenile Graves' Ophthalmopathy on Graves' Disease Course
- PMID: 29225963
- PMCID: PMC5684562
- DOI: 10.1155/2017/4853905
The Influence of Juvenile Graves' Ophthalmopathy on Graves' Disease Course
Abstract
Purpose: To investigate juvenile Graves' ophthalmopathy (GO) signs and compare Graves' disease (GD) course in patients with or without GO.
Patients and methods: There were analyzed data (visual acuity, proptosis, palpebral fissure measurements, clinical activity score (CAS), and the course of GD) of 67 children who have been newly diagnosed with GD. 26.9% of patients with GD had signs of ophthalmopathy (GO+), and 73.1% were without ophthalmopathy (GO-).
Results: Upper eyelid retraction (72.3%), proptosis (66.7%), and soft tissue changes (27.8-38.9%) were in GO+ patients. The palpebral fissure, CAS, and proptosis values were greater in the GO+ group than in the GO- group (p < 0.001). GD course in GO+ patients was longer than that in GO- patients (p < 0.001). The duration of the first remission was longer in GO- than in GO+ patients (p < 0.001). The duration of first remission was longer than one year for 61.2% in GO- and 33.3% in GO+ patients (p < 0.02).
Conclusion: The common manifestations of juvenile GO patients were upper eyelid retraction, proptosis, and soft tissue involvement. The study demonstrates that pediatric patients with GO are more likely to have a severe course of autoimmune thyroid disease.
Similar articles
-
Predictive Factors of Development of Graves' Ophthalmopathy for Patients with Juvenile Graves' Disease.Int J Endocrinol. 2016;2016:8129497. doi: 10.1155/2016/8129497. Epub 2016 Jun 16. Int J Endocrinol. 2016. PMID: 27413373 Free PMC article.
-
Association of clinical course with thyroid-stimulating immunoglobulin in Graves' ophthalmopathy in Mongolians.PLoS One. 2022 Nov 17;17(11):e0277055. doi: 10.1371/journal.pone.0277055. eCollection 2022. PLoS One. 2022. PMID: 36395261 Free PMC article.
-
Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?Int J Environ Res Public Health. 2019 Jan 8;16(1):155. doi: 10.3390/ijerph16010155. Int J Environ Res Public Health. 2019. PMID: 30626069 Free PMC article.
-
The efficacy and safety of selenium supplementation versus placebo in the treatment of Graves' orbitopathy: A systematic review and meta-analysis of randomised controlled trials.Clin Endocrinol (Oxf). 2024 Dec;101(6):669-681. doi: 10.1111/cen.15128. Epub 2024 Aug 13. Clin Endocrinol (Oxf). 2024. PMID: 39138905
-
Graves' ophthalmopathy.Med Clin North Am. 1995 Jan;79(1):195-209. doi: 10.1016/s0025-7125(16)30092-x. Med Clin North Am. 1995. PMID: 7808092 Review.
Cited by
-
Clinical significance of thyroglobulin antibodies and thyroid peroxidase antibodies in Graves' disease: a cross-sectional study.Hormones (Athens). 2023 Jun;22(2):253-261. doi: 10.1007/s42000-023-00437-7. Epub 2023 Feb 22. Hormones (Athens). 2023. PMID: 36811756
-
2022 European Thyroid Association Guideline for the management of pediatric Graves' disease.Eur Thyroid J. 2022 Jan 1;11(1):e210073. doi: 10.1530/ETJ-21-0073. Eur Thyroid J. 2022. PMID: 34981748 Free PMC article.
-
Symptoms and signs of dry eye in children with Graves' ophthalmopathy.Saudi J Ophthalmol. 2023 Feb 17;37(2):149-153. doi: 10.4103/sjopt.sjopt_47_22. eCollection 2023 Apr-Jun. Saudi J Ophthalmol. 2023. PMID: 37492217 Free PMC article.
References
-
- Lee S. H., Lee S. Y., Chung H. R., et al. Remission rate and remission predictors of Graves’ disease in children and adolescents. Korean Journal of Pediatrics. 2009;52(9):1021–1028. doi: 10.3345/kjp.2009.52.9.1021. - DOI
-
- Rivkees S. A. Treatment of hyperthyroidism due to Graves’ disease in children. In: Krassas G. E., Rivkees S. A., Kiess W., editors. Diseases of the Thyroid in Childhood and Adolescence. Basel: Karger; 2007. pp. 169–191. - DOI
LinkOut - more resources
Full Text Sources
Other Literature Sources